Selection of news regarding the sigma-tau Group

`Resistance is developing in the Thai-Cambodian border zone. And it spreads very quickly`.  [...]

Attachment:

 AUTHORIZATION EMA - GENEVE 30th November 2011

Attachment:

 PRESS REVIEW - NEWS MALARIA - BARCELLONA 5th October 2011

Attachment:

Cambridge, MA, January 11, 2011 – Dyax Corp. (NASDAQ: DYAX) and Defiante Farmaceutica S.A., an affiliate of the pharmaceutical group Sigma-Tau (Sigma-Tau), announced today the expansion of their partnership to commercialize KALBITOR® (ecallantide) for the treatment of hereditary angioedema [...]

Attachment:

Finding new uses for old drugs is a tempting strategy for pharmaceutical companies, but the longer a medicine has existed [...]

Attachment:

 Emma Dorey .

There are many drugs available to treat high blood pressure, but finding one that works for a particular patient has been hit and miss. Now, researchers in Italy have discovered a genetic profile that can identify patients [...]

Attachment:

Whether the powerful highblood pressure medicine rostafuroxin will be effective for a particular patient can be predicted from a set of gene variants. Giuseppe Bianchi at the [...]

Attachment:

 Investigadores del Instituto de Investigación Prassis Sigma-Tau en Milan (Italia) han utilizado una combinación de genes clave y han desarrollado un perfil genético que puede identificar al menos a una cuarta parte de los [...]

Attachment:

Milan, 25 November 2010 – Researchers at Prassis (Sigma-Tau Group) and San Raffaele University Scientific Institute of Milan have demonstrated the effectiveness of a new pharmacogenomic therapeutical approach for the fight against hypertension. The research results have been published today in the highly-esteemed scientific journal Science Translation Medicine [...]

Attachment:

La société américaine Enzon Pharmaceuticals a annoncé hier la vente de ses activités de spécialités pharmaceutiques au laboratoire italien Sigma-Tau. La transaction s`élève à près de 327 millions de dollars. L`entreprise américaine, spécialisée dans le développement de médicaments pour les malades du cancer, touchera également une redevance allant de 5 % à 10 % du montant des ventes des quatre produits cédés à son concurrent, et ce jusqu`en 2014. L`opération sera effective au premier trimestre de l`année prochaine. Enzon souhaite maintenant se recentrer sur son activité de plate-forme technologique.

Attachment:

La société américaine Enzon a annoncé lundi la cession de son activité de médicaments de spécialistes à l`italien Sigma-Tau pour un montant pouvant aller jusqu`à 327 millions de dollars, en numéraire. Enzon va initialement recevoir 300 millions de dollars puis un montant additionnel allant jusqu`à 27 millions en fonction de la performance des produits. Il percevra des royalties de 5% à 10% sur les ventes.

Attachment:

Sigma-Tau Pharmaceuticals of Gaithersburg, a wholly owned subsidiary of Sigma-Tau Group of Italy, is buying
the specialty pharmaceutical business of Enzon Pharmaceuticals of Bridgewater, N.J., for up to $327 million. The deal, which also includes a manufacturing plant in Indianapolis, comprises $300 million, plus up to $27 million based on success milestones. In addition, Enzon will also receive royalties of 5 percent to 10 percent on
incremental net sales above a 2009 baseline amount from Enzon`s four marketed specialty drugs through 2014.

Attachment:

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. Enzon will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products through 2014.

Attachment:

Shares in Enzon Pharmaceuticals rose by 9.5% to close at $9.83 on November 9th after it announced the sale of its marketed products business. It has agreed to sell its four speciality pharmaceutical products to Italy`s sigma-tau Group for $300 million plus up to $27 million in milestones and certain royalties…

Attachment:

Enzon Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones.

Attachment: